Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate Neurotoxicity
- Autores: Povarnina P.Y.1, Kolyasnikova K.N.1, Nikolaev S.V.2, Antipova T.A.2, Gudasheva T.A.1
- 
							Afiliações: 
							- Laboratory of Peptide Bioregulators
- Laboratory of Pharmacology of Neuroprotection, V. V. Zakusov Research Institute of Pharmacology
 
- Edição: Volume 160, Nº 5 (2016)
- Páginas: 653-655
- Seção: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/236862
- DOI: https://doi.org/10.1007/s10517-016-3241-5
- ID: 236862
Citar
Resumo
We studied cerebroprotective properties of neuropeptide cycloprolylglycine (1 mg/kg) administered intraperitoneally to rats with modeled incomplete global ischemia rats and neuroprotective properties for HT-22 cells under conditions of glutamate toxicity. It was shown that the neuropeptide administered during the postischemic period restored the neurological status of rats by preventing sensorimotor impairments in the limb-placing test and suppression of locomotor activity in the open field test. In in vitro experiments, cycloprolylglycine in concentrations of 10–5-10–8 M exhibited pronounced dose-dependent neuroprotective activity. The results attest to high cerebro- and neuroprotective potential of endogenous peptide cycloprolylglycine.
Sobre autores
P. Povarnina
Laboratory of Peptide Bioregulators
							Autor responsável pela correspondência
							Email: povarnina@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
K. Kolyasnikova
Laboratory of Peptide Bioregulators
														Email: povarnina@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
S. Nikolaev
Laboratory of Pharmacology of Neuroprotection, V. V. Zakusov Research Institute of Pharmacology
														Email: povarnina@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
T. Antipova
Laboratory of Pharmacology of Neuroprotection, V. V. Zakusov Research Institute of Pharmacology
														Email: povarnina@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
T. Gudasheva
Laboratory of Peptide Bioregulators
														Email: povarnina@gmail.com
				                					                																			                												                	Rússia, 							Moscow						
Arquivos suplementares
 
				
			 
						 
						 
						 
						 
					 
				 
  
  
  
  
  Enviar artigo por via de e-mail
			Enviar artigo por via de e-mail  Acesso aberto
		                                Acesso aberto Acesso está concedido
						Acesso está concedido Somente assinantes
		                                		                                        Somente assinantes
		                                					